NCT05356013View on ClinicalTrials.gov

Caplyta in Borderline Personality Disorder

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Borderline Personality Disorder
Interventions
DRUG

Caplyta

Atypical antipsychotic

DRUG

Placebo

Pill that contains no medicine.

Trial Locations (1)

60637

University of Chicago Medical Center, Chicago

Sponsors
All Listed Sponsors
collaborator

Intra-Cellular Therapies, Inc.

INDUSTRY

lead

University of Chicago

OTHER